Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals

AIDS Research and Therapy

Volumn 3, Issue 1, 2006, Pages

  Bunupuradah, Torsak ^a   Wannachai, Siripan ^a   Chuamchaitrakool, Arpa ^a   Intasan, Jintana ^a   Nuchapong, Thantip ^a   Neiss, Woodie ^b   Kramm, Kenny ^b   Pancharoen, Chitsanu ^c   Burger, David ^d   Ananworanich, Jintanat ^a  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b FLAVORx Inc   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIR; DIDANOSINE; DIVIR; EFAVIRENZ; FLAVORING AGENT; INDINAVIR; LAMIVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NERAVIR; NEVIRAPINE; STAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CHILD; CLINICAL TRIAL; DRUG CAPSULE; DRUG FORMULATION; FEMALE; FLAVOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; TABLET; TASTE; THAILAND;

EID: 33846671552     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-3-30     Document Type: Article

References (11)

1. National ARV for people living with HIV AIDS (NAPHA project) Bureau of AIDS, TB and STI, Department of disease control, MOPH, Thailand 2006 http://www.AIDSTHAI.org Accessed 13 December 2006.
2. Guideline for the use of antiretroviral agents in pediatric HIV infection March 24, 2005 AIDSinfo 2005 http://aidsinfo.nih.gov/ Accessed 19 December 2005.
3. Watson DC Farley JJ Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1 Pediatr Infect Dis J 1999 18 682-9 10.1097/ 00006454-199908000-00006 10462336
4. Van dyke RB Lee S Johnson GM Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection Peadiatrics 2002 109 e61 10.1542/ peds.109.4.e61
5. Tuboi SH Harrison LH Sprinz E Albernaz RK Schechter M Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil J Acquir Immune Defic Syndr 2005 140 324-328
6. Maggiolo F Ravasio L Ripamonti D Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors Clin Infect Dis 2005 1 40 158-63 Epub 2004 Dec 6. 10.1086/426595
7. Christine Jaderlund The impact of a commercially available medication flavoring system (FLAVORx©) on pediatric inpatients admitted to a children's Hospital Poster presentation: 14th Pediatric Pharmacy Conference: PPAG Annual Meeting, Chicago, USA October 9-12, 2005.
8. Christine Jaderlund The impact of a commercially available medication flavoring system (FLAVORx©) on pediatric inpatients admitted to a children's Hospital J Pediatr Pharmacol Ther 2005 10 2 124-5
9. NIAID PEDIATRIC AIDS CLINICAL TRIALS GROUP (PACTG) PEDIATRIC INTERNATIONAL ADHERENCE QUESTIONNAIRE Behavior/Identification QL5030 (P0000)/00-00-00. PEDIATRIC AIDS CLINICAL TRIALS GROUP 2005 https://www.fstrf.org/qol/pactg/ql5030.pdf Accessed 19 December 2005.
10. Revised Human Immunodeficiency Virus Pediatric Classification System Clinical Categories, Centers for Disease Control and Prevention.1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age MMWR 1994 43 RR-12 1-10
11. John G Bartlett, Drug table 2. Antiretroviral agents, Target Serum Levels and CSF: Plasma ratio John Hopkins University School of Medicine, Pocket Guide to adult HIV/AIDS treatment, Jan 2005